TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TuHURA Biosciences, Inc. (NASDAQ:HURA), a leading Phase 3 immuno-oncology company, has announced its participation in two upcoming investor conferences set for March 2026. Dr. James Bianco, the CEO and President of TuHURA, will represent the company at these events, highlighting TuHURA's commitment to developing innovative therapies that target cancer treatment resistance.

The first event, the Citizens Life Science Conference, is scheduled for Tuesday, March 10, 2026, at 4:00 PM ET. Attendees can register to view Dr. Bianco's presentation live, which will also be available as an archived webcast on TuHURA's investor relations website. The second conference is the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, where TuHURA will engage in one-on-one meetings with investors.

TuHURA is focused on overcoming primary and acquired resistance to cancer immunotherapy, addressing significant challenges that often render these treatments ineffective. The company’s lead candidate, IFx-2.0, is an innate immune agonist specifically designed to enhance the efficacy of the checkpoint inhibitor Keytruda® (pembrolizumab) in treating advanced or metastatic Merkel Cell Carcinoma. A Phase 3 clinical trial for IFx-2.0 has been initiated to evaluate its effectiveness compared to a placebo.

Moreover, TuHURA's portfolio includes TBS-2025, a VISTA inhibiting monoclonal antibody acquired through its merger with Kineta Inc. This product is advancing into Phase 2 development for use in cases of acute myeloid leukemia (AML). Additionally, TuHURA is leveraging proprietary technologies to create first-in-class therapeutics aimed at bolstering immune response against tumors.

For more details on the company and its innovations, visit TuHURA’s official website.

TuHURA Biosciences (NASDAQ: HURA) has recently announced its participation in key upcoming investor conferences, which presents a strategic opportunity for investors to evaluate the company's growth potential in the immuno-oncology sector. As a Phase 3 company specializing in developing therapeutics that target resistance to cancer immunotherapy, TuHURA is well-positioned within a rapidly evolving healthcare landscape.

The upcoming conferences—the Citizens Life Science Conference on March 10 and the Leerink Global Healthcare Conference on March 11—are critical for TuHURA as they provide a platform to engage with potential investors. The presence of Dr. James Bianco, the CEO, underscores the company's commitment to transparency and investor relations, which can increase shareholder confidence.

TuHURA's lead candidate, IFx-2.0, is currently undergoing a Phase 3 trial aimed at treating Merkel Cell Carcinoma, leveraging its innovative mechanisms to overcome resistance to existing therapies like Keytruda. As resistance to cancer treatments continues to be a major hurdle, TuHURA's focus on this area could distinguish it from competitors, particularly if trial results are favorable.

Moreover, the acquisition of TBS-2025 signals a strategic expansion of its portfolio, potentially enhancing the company’s capabilities in treating acute myeloid leukemia (AML). This diversification not only mitigates risk but also presents multiple avenues for growth.

Investors should closely monitor the outcomes of these conferences, as updates on trial results and corporate strategy could significantly impact stock performance. It's also wise to keep an eye on broader market trends in biotechnology and the immuno-oncology space, as they can influence investor sentiment. Given the potential upside, TuHURA could represent an appealing investment opportunity for those willing to embrace the inherent risks of the biotech sector.